The healthcare diagnostics company has received CE-certification for its rapid CYP2C19 ID Kit, which identifies genetic variants that impact the effectiveness of the antiplatelet drug Clopidogrel.
The healthcare diagnostics company has received a £120,000 order for its CYP2C19-ID Kit, which will be used to support the expansion of the kit's use into Acute Coronary Syndrome.
The healthcare diagnostics company has provided an update on the certification process for one of its key products, the CYP2C19 ID Kit.
The healthcare diagnostics company has secured additional grant funding to further progress its DEVOTE project, which aims to accelerate the adoption of genomic technology into clinical practice.
The healthcare diagnostics company has received an R&D tax credit, providing a financial boost.
The healthcare diagnostics company has completed a £1.23 million fundraise through a retail offer, with the new shares issued at a small discount to the previous closing price.
The healthcare diagnostics company is raising funds through a retail offer of new shares, providing existing shareholders the opportunity to participate.
The pharmacogenetic testing company reported progress in product adoption and regulatory advancements, but faces significant financial challenges with increasing losses and diminishing cash reserves.
The healthcare diagnostics company has conditionally raised £1 million through a discounted share placing, providing additional working capital as it pursues commercial opportunities.
The healthcare diagnostics company announces that the Scottish Government will invest in national rollout of its pharmacogenetic testing kits for stroke patients and newborn babies.